TrialJournal of Alzheimer's disease : JAD2022

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial.

Xue Hua et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.